CorMedix Inc (CRMD) Expected to Announce Quarterly Sales of $240,000.00

Equities analysts forecast that CorMedix Inc (NASDAQ:CRMD) will announce sales of $240,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for CorMedix’s earnings. The highest sales estimate is $350,000.00 and the lowest is $130,000.00. CorMedix reported sales of $90,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 166.7%. The company is scheduled to report its next quarterly earnings results after the market closes on Thursday, March 14th.

On average, analysts expect that CorMedix will report full-year sales of $650,000.00 for the current financial year, with estimates ranging from $540,000.00 to $750,000.00. For the next fiscal year, analysts anticipate that the business will post sales of $3.38 million, with estimates ranging from $430,000.00 to $6.32 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for CorMedix.

Separately, Roth Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of CorMedix in a research note on Thursday, December 6th.

Shares of CRMD opened at $1.80 on Tuesday. CorMedix has a twelve month low of $0.17 and a twelve month high of $2.74.

CorMedix Company Profile

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Recommended Story: What is a closed-end mutual fund (CEF)?

Get a free copy of the Zacks research report on CorMedix (CRMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with's FREE daily email newsletter.